Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Pravcomission did not approve the sale of a stake in Moscow Exchange

11/3/23 MOEX

Pravcomission did not approve the sale of a stake in Moscow Exchange

11/3/23 SOFL

NLMK reported for 6 months of 2023 by RAS

11/3/23 NLMK

Belavia counts on the purchase to MC-21 and Superjet

11/3/23 IRKT

Nornickel will carry out a share split

11/3/23 GMKN

Board of Directors of MMC Norilsk Nickel recommended that dividends be paid for 9 months 2023

11/3/23 GMKN

SPB Exchange resumes trading in Russian securities

11/3/23 SPBE

GIT reported for 9 months of 2023 by RAS

11/3/23 GRNT

SPB Exchange will withdraw from the capital of Kazakhstan's ITS

11/3/23 SPBE

YES! discounters' revenue grew 18.9% in the first nine months of 2023

11/3/23 OKEY